CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis, and nephrology. Since its start in 1916, the company has been driven by its promise to save lives using the latest technologies. Today, CSL, including its businesses, CSL Behring, CSL Seqirus, and CSL Vifor, provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Its unique combination of commercial strength, R&D focus, and operational excellence enables it to identify, develop, and deliver innovations so that patients can live life to the fullest.
See their community guidelines here: https://bit.ly/3Bs17Ra
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $111.00M | - | 06 Feb 2004 |
No recent news or press coverage available for CSL.
We care about your data, and we'd love to use cookies make your experience better.
